Clinical Trials Logo

Alopecia, Androgenetic clinical trials

View clinical trials related to Alopecia, Androgenetic.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05802173 Completed - Clinical trials for Alopecia, Androgenetic

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

Start date: March 6, 2023
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia

NCT ID: NCT05296863 Completed - Clinical trials for Alopecia, Androgenetic

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

Start date: October 11, 2021
Phase: Phase 3
Study type: Interventional

This study investigated the efficacy of adipose derived stem cell conditioned media (ADSC-CM) combined with minoxidil for hair regeneration therapy in male AGA.

NCT ID: NCT05244980 Completed - Clinical trials for Alopecia, Androgenetic

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).

NCT ID: NCT04913519 Completed - Clinical trials for Alopecia, Androgenetic

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

AGA
Start date: April 27, 2021
Phase: Phase 1
Study type: Interventional

Multi-center, fixed volume, randomized, double-blind, vehicle-controlled, parallel group, dose escalation comparison study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).

NCT ID: NCT03004469 Completed - Clinical trials for Alopecia, Androgenetic

Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

Start date: August 2, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to confirm the clinical efficacy and the safety of P-3074 in participants with androgenetic alopecia.

NCT ID: NCT02503852 Completed - Clinical trials for Alopecia, Androgenetic

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

STYLE
Start date: November 2015
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the safety and feasibility of the Celution and Puregraft Systems in the processing and preparation of an autologous fat graft enriched with adipose-derived regenerative cells (ADRCs) in the treatment of early alopecia androgenetica.

NCT ID: NCT01904721 Completed - Alopecia Clinical Trials

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Start date: August 2013
Phase: Phase 2
Study type: Interventional

This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).

NCT ID: NCT01325337 Completed - Alopecia Clinical Trials

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Start date: June 2011
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.

NCT ID: NCT01189279 Completed - Alopecia Clinical Trials

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.